What is the health insurance coverage for cimepilimab? How to apply for reimbursement?

Cemiplimab (Cemiplimab) is an immune checkpoint inhibitor mainly used to treat advanced cutaneous squamous cell carcinoma (CSCC) and other related tumors. Although cimepilimab has been approved in many countries around the world and has been used for clinical treatment, this drug is not currently available in the Chinese market and is therefore not covered by medical insurance. Due to the high price of the original drug of cimepilimab, it is expected that each box may be sold for between RMB 40,000 and RMB 100,000. Therefore, if this drug is launched in the future and included in medical insurance, it may bring a certain financial burden to patients.

Currently, cimepilimab has not been approved for marketing in China. Although the drug is already available in the U.S. and European markets, due to the complicated drug approval process in China, the price information of the drug is currently unclear, and no generic drugs have emerged. For patients, if the drug is approved and launched in China in the future, it may take a certain period of time before it can be reimbursed through medical insurance or other channels. The coverage of medical insurance generally depends on the clinical effect of the drug, its price and the country's drug procurement policy.

Once cimepilimab enters the Chinese market and is covered by medical insurance, patients will be able to reimburse part of the cost of the drug through medical insurance. Usually, applying for drug reimbursement requires certain procedures. First, patients need to consult the local hospital pharmacy to find out whether the drug has been included in the medical insurance catalog. If the drug has been included in the medical insurance, the patient needs to provide relevant medical information and diagnosis certificate, and only after approval by the hospital can it be reimbursed according to the proportion of the medical insurance policy. If the drug is not covered by medical insurance, patients may need to pay for it through commercial insurance or out-of-pocket.

Reference materials:https://www.libtayohcp.com/